Halozyme Therapeutics (HALO) EBT Margin (QoQ) (2010 - 2026)

Halozyme Therapeutics (HALO) EBT Margin (QoQ) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Halozyme Therapeutics 11.25 Bn 11.02 Bn 401.83 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 1,136.00
Mar 31, 2026 7,019.00
Dec 31, 2025 -8,413.00
Sep 30, 2025 -111.00
Jun 30, 2025 862.00
Mar 31, 2025 -550.00
Dec 31, 2024 287.00
Sep 30, 2024 604.00
Jun 30, 2024 187.00
Mar 31, 2024 504.00
Dec 31, 2023 -312.00
Sep 30, 2023 496.00
Jun 30, 2023 993.00
Mar 31, 2023 -679.00
Dec 31, 2022 373.00
Sep 30, 2022 1,557.00
Jun 30, 2022 -4,375.00
Mar 31, 2022 971.00
Dec 31, 2021 -1,024.00
Sep 30, 2021 -309.00